Ucb SA 2009 SR
The report marks UCB's first Corporate Social Responsibility report, focusing on four pillars: patients, people, ethics, and planet. Key highlights include the launch of three innovative therapies (Cimzia, Vimpat, and Neupro) and an investment of €674 million in R&D. The company implemented the SHAPE transformation program, resulting in a 22% workforce reduction while maintaining patient supply. Environmental efforts included achieving 28% green electricity usage and reducing CO2 emissions. The report follows GRI G3 guidelines at a C+ application level with external assurance.
Company: Ucb SA
Sector: Manufacturing
Country: Belgium
Year: 2009
Type: SR
Pages: 42
Back to company
Ucb SA
Corporate Social Responsibility Report
The report marks UCB's first Corporate Social Responsibility report, focusing on four pillars: patients, people, ethics, and planet. Key highlights include the launch of three innovative therapies (Cimzia, Vimpat, and Neupro) and an investment of €674 million in R&D. The company implemented the SHAPE transformation program, resulting in a 22% workforce reduction while maintaining patient supply. Environmental efforts included achieving 28% green electricity usage and reducing CO2 emissions. The report follows GRI G3 guidelines at a C+ application level with external assurance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2009
Reporting Period
Jan 1, 2009 - Dec 31, 2009
Fiscal Year
2009
Published
May 20, 2010
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Water Consumption
Total Waste
Women in Management
Workplace Fatalities
Employees